Author Archives: Diana Campelo Delgado

Lexeo Licenses Rights to Potential Gene Therapy LX2006

Lexeo Therapeutics has entered an agreement with Adverum Biotechnologies to license Adverum’s intellectual property rights and pre-clinical data of LX2006, an investigational gene therapy for Friedreich’s ataxia (FA). Lexeo will continue to advance the gene therapy program through pre-clinical studies that support an investigational new drug (IND) application,…